Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Acadia Pharmaceuticals Inc. ("Acadia " or "the Company") (NASDAQ:ACAD). Investors who purchased Acadia securities prior to September 9, 2019, and conti...
2024-03-25 11:30:02 ET RBC Capital analyst issues BUY recommendation for ACAD on March 25, 2024 10:00AM ET. The previous analyst recommendation was Buy. ACAD was trading at $17.85 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-03-20 12:30:27 ET Summary Taysha Gene Therapies, Inc. cohort 2 higher dosing TSHA-102 data from adolescent and adult phase 1/2 REVEAL study treating patients with Rett Syndrome is expected in 2nd half of 2024. Cohort 1 data of TSHA-102 treating pediatric patients with Rett Sy...
2024-03-19 10:16:19 ET Summary Biotech M&A activity surged at the end of 2023, which helped the small biotech sector surge by 50% off its late October lows. Deal volume should remain strong in 2024 as large pharma concerns have large cash balances, face key patent expirations ...
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time. The conference will be held virtually. A live webcast of Acadia’s presentation will be accessible on the company’s ...
2024-03-13 09:23:16 ET Summary Acadia's new drug, Daybue, shows promising initial sales, but pimavanserin failed in schizophrenia trials, impacting stock value. Nuplazid's patent protection may shield it from generic competition until at least 2030, with steady sales growth report...
2024-03-12 15:00:09 ET Summary Acadia Pharmaceuticals stock price dropped over 15% after its drug candidate, pimavanserin, failed to meet the primary endpoint in a Phase 3 study in negative symptoms of schizophrenia. The setback adds to previous rejections of pimavanserin for othe...
2024-03-12 10:39:56 ET More on Acadia Pharma Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing Acadia Pharmaceuticals: Daybue Growth Concerns, Important Data Readout Coming ACADIA Pharmaceuticals Inc. (ACAD) Q4 2023 Earnings Call Transcript ...
2024-03-12 08:28:49 ET More on Pre-market losers & stocks. Renalytix approached by potential buyer, stock rallies 28% Renalytix surges after Medicare draft decision on lead product Seeking Alpha’s Quant Rating on ASLAN Pharmaceuticals Historical ea...
2024-03-12 05:14:45 ET More on related stocks: Vail Resorts, Inc. (MTN) Q2 2024 Earnings Call Transcript Oracle Corporation (ORCL) Q3 2024 Earnings Call Transcript Bilibili Stock Downgraded To Sell After Assessing Q4 Earnings Oracle in charts: Cloud services ...
News, Short Squeeze, Breakout and More Instantly...
ACADIA Pharmaceuticals Inc. Company Name:
ACAD Stock Symbol:
NASDAQ Market:
ACADIA Pharmaceuticals Inc. Website:
2024-04-30 08:30:07 ET UBS analyst issues BUY recommendation for ACAD on April 30, 2024 06:00AM ET. The previous analyst recommendation was Buy. ACAD was trading at $17.1 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...
-- 10 academic scholarships awarded supporting siblings of Rett syndrome patients Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship progra...
Company to host conference call and webcast on Wednesday, May 8, 2024, at 4:30 p.m. Eastern Time Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. A...